DGI recommendations for COVID-19 pharmacotherapy
Infection
.
2021 Apr;49(2):369-370.
doi: 10.1007/s15010-020-01519-z.
Epub 2020 Oct 19.
Authors
Jakob J Malin
1
2
,
Christoph D Spinner
3
;
German Society of Infectious Diseases (DGI)
Affiliations
1
Division of Infectious Diseases, Department I of Internal Medicine, University of Cologne, Cologne, Germany. jakob.malin@uk-koeln.de.
2
Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. jakob.malin@uk-koeln.de.
3
Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
PMID:
33074366
PMCID:
PMC7569361
DOI:
10.1007/s15010-020-01519-z
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Drug Treatment*
Germany
Humans
Infectious Disease Medicine / organization & administration
Infectious Disease Medicine / standards*
Practice Guidelines as Topic
SARS-CoV-2